Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 3/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.37 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL29226934 | 1.00 | — | — | |
| Acetic Acid SCHEMBL1879030 | 0.96 | FFAR3 (0.64) | FFAR3LCKFYNTSHRLMNA | |
| Acetic Acid SCHEMBL17909908 | 0.96 | FFAR3 (0.64) | FFAR3LCKFYNTSHRLMNA | |
| Acetic Acid SCHEMBL36527 | 0.96 | — | — | |
| Acetic Acid SCHEMBL2516097 | 0.96 | FFAR3 (0.64) | FFAR3LCKFYNTSHRLMNA | |
| Acetic Acid SCHEMBL7784606 | 0.96 | FFAR3 (0.64) | FFAR3LCKFYNTSHRLMNA | |
| Acetic Acid SCHEMBL139024 | 0.96 | FFAR3 (0.64) | FFAR3LCKFYNTSHRLMNA | |
| Acetic Acid SCHEMBL1578192 | 0.96 | FFAR3 (0.64) | FFAR3LCKFYNTSHRLMNA | |
| Acetic Acid SCHEMBL8888237 | 0.96 | FFAR3 (0.64) | FFAR3LCKFYNTSHRLMNA | |
| Acetic Acid SCHEMBL2959365 | 0.93 | FFAR3 (0.50) | FFAR3LCKFYNTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118330198-A | Blood analysis and detection method and system | 西安国联质量检测技术股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-115836058-A | Benzisoxazole derivatives | 住友制药株式会社 | 2023-03-21 | — | — | CN | disclosed |
| WO-2021215423-A1 | COSMETIC PREPARATION | 株式会社 資生堂 (JP) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021215211-A1 | COSMETIC | 株式会社 資生堂 (JP) | 2021-10-28 | — | — | WO | disclosed |
| CN-113396225-A | Dynamic analysis method of intracellular compound | 株式会社日立高新技术 | 2021-09-14 | — | — | CN | disclosed |
| CN-112689636-A | Novel heteroatom aromatic amide derivative and drug containing the same | 科研制药株式会社 | 2021-04-20 | — | — | CN | disclosed |
| EP-1880711-B1 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO CO LTD (JP) | 2016-07-20 | — | — | EP | disclosed |
| US-9177691-B2 | Polarizable nanoparticles and electrorheological fluid comprising same | BAKER HUGHES INCORPORATED (US) | 2015-11-03 | — | — | US | disclosed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| WO-2013043677-A1 | POLARIZABLE NANOPARTICLES AND ELECTRORHEOLOGICAL FLUID COMPRISING SAME | BAKER HUGHES INCORPORATED (US) | 2013-03-28 | — | — | WO | disclosed |
| US-20130069022-A1 | POLARIZABLE NANOPARTICLES AND ELECTRORHEOLOGICAL FLUID COMPRISING SAME | BAKER HUGHES INCORPORATED (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20090215893-A1 | Parakeratosis inhibitor, pore-shrinking agent,or rough skin preventing/ameliorating agent, and external composition for skin | SHISEIDO COMPANY LTD (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-1884230-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT OR AGENT FOR PREVENTING/AMELIORATING ROUGH SKIN AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-02-06 | — | — | EP | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | FFAR3 4404/4885LCK 3429/4885FYN 4232/4885 |
| US-20090215893-A1 | Parakeratosis inhibitor, pore-shrinking agent,or rough skin preventing/ameliorating agent, and external composition for skin | CUTA, STOM, MTOR | FFAR3 4555/4885LCK 1819/4885FYN 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.